| Literature DB >> 33878351 |
Thomas N Vilches1, Shokoofeh Nourbakhsh2, Kevin Zhang3, Lyndon Juden-Kelly4, Lauren E Cipriano5, Joanne M Langley6, Pratha Sah7, Alison P Galvani8, Seyed M Moghadas9.
Abstract
The novel coronavirus disease 2019 (COVID-19) has caused severe outbreaks in Canadian long-term care facilities (LTCFs). In Canada, over 80% of COVID-19 deaths during the first pandemic wave occurred in LTCFs. We sought to evaluate the effect of mitigation measures in LTCFs including frequent testing of staff, and vaccination of staff and residents. We developed an agent-based transmission model and parameterized it with disease-specific estimates, temporal sensitivity of nasopharyngeal and saliva testing, results of vaccine efficacy trials, and data from initial COVID-19 outbreaks in LTCFs in Ontario, Canada. Characteristics of staff and residents, including contact patterns, were integrated into the model with age-dependent risk of hospitalization and death. Estimates of infection and outcomes were obtained and 95% credible intervals were generated using a bias-corrected and accelerated bootstrap method. Weekly routine testing of staff with 2-day turnaround time reduced infections among residents by at least 25.9% (95% CrI: 23.3%-28.3%), compared to baseline measures of mask-wearing, symptom screening, and staff cohorting alone. A similar reduction of hospitalizations and deaths was achieved in residents. Vaccination averted 2-4 times more infections in both staff and residents as compared to routine testing, and markedly reduced hospitalizations and deaths among residents by 95.9% (95% CrI: 95.4%-96.3%) and 95.8% (95% CrI: 95.5%-96.1%), respectively, over 200 days from the start of vaccination. Vaccination could have a substantial impact on mitigating disease burden among residents, but may not eliminate the need for other measures before population-level control of COVID-19 is achieved.Entities:
Keywords: Agent-based simulations; COVID-19; Long-term care; Testing; Vaccination
Year: 2021 PMID: 33878351 PMCID: PMC8053216 DOI: 10.1016/j.ypmed.2021.106564
Source DB: PubMed Journal: Prev Med ISSN: 0091-7435 Impact factor: 4.018
Fig. 1Incidence of infection per 1000 residents (A,D), cumulative infections per 1000 residents (B,E), and relative reduction of cumulative infections (attack rate), hospitalizations, and deaths with routine testing of staff (C) and vaccination of residents and staff (F), over a 200-day time period of simulations. Intervention scenarios (in addition to baseline control measures) included: weekly routine testing of staff with NP sampling and 1-day (S1a) and 2-day (S1b) turnaround; saliva sampling with 1-day (S2a) and 2-day (S2b) turnaround; and vaccination (S3).
Model parameters and their estimated value.
| Model parameter | Staff | Resident | Source | |||||
|---|---|---|---|---|---|---|---|---|
| Age group | 20–49 | 50–64 | <60 | 60–69 | 70–79 | 80–89 | 90+ | |
| Transmission probability per contact during pre-symptomatic stage | 0.0438 | ( | ||||||
| Calibrated to incidence data for LTCFs in Ontario | ||||||||
| Incubation period (days) | Log-Normal(shape: 1.434, scale: 0.661) | ( | ||||||
| Asymptomatic period (days) | Gamma(shape: 5, scale: 1) | Derived from ( | ||||||
| Pre-symptomatic period (days) | Gamma(shape: 1.058, scale: 2.174) | ( | ||||||
| Infectious period from onset of symptoms (days) | Gamma(shape: 2.768, scale: 1.1563) | Derived from ( | ||||||
| Proportion of individuals with comorbidities | 0.18 | 0.38 | 1 | ( | ||||
| Proportion of infected individuals developing asymptomatic infection | 0.328 | 0.328 | 0.328 | 0.258 | 0.188 | 0.188 | 0.188 | ( |
| Proportion of symptomatic cases developing severe illness | 0.15 | 0.40 | 0.8 | ( | ||||
| Hospitalization rate of symptomatic cases | 23.5% | 23.5% | 18.2% | 15.1% | 13.4% | 9.3% | 7.1% | ( |
| Case fatality rate | 0.21% | 0.21% | 8.4% | 18.8% | 24.1% | 27.9% | 35.4% | ( |
| Length of hospital stay | Gamma(shape: 4.5, scale: 2.75) | ( | ||||||
Mean and 95% credible intervals for the reduction of cumulative infections, hospitalizations, and deaths among residents achieved by additional measures of 7-day routine testing of staff and vaccination of staff and residents, as compared with baseline measures alone, over a 200-day time horizon.
| Measure | Mean relative reduction (%) and 95% CrI | |||
|---|---|---|---|---|
| 7-day routine testing | Infection | Hospitalization | Death | |
| NP sampling | 1-day turnaround | 42.1 (40.3, 43.9) | 42.4 (39.7, 45.2) | 43.2 (41.3, 45.4) |
| 2-day turnaround | 30.3 (28.4, 32.3) | 29.9 (26.6, 33.0) | 31.0 (28.9, 33.2) | |
| Saliva sampling | 1-day turnaround | 34.3 (32.2, 36.2) | 34.4 (31.1, 37.1) | 34.6 (32.4, 36.9) |
| 2-day turnaround | 25.9 (23.3, 28.3) | 23.9 (20.4, 27.1) | 26.1 (23.5, 28.6) | |
| Vaccination | 88.5 (88.1, 88.9) | 95.9 (95.4, 96.3) | 95.8 (95.5, 96.1) | |
Mean and 95% credible intervals for the reduction of cumulative infections, hospitalizations, and deaths among staff achieved by additional measures of 7-day routine testing of staff and vaccination of staff and residents, as compared with baseline measures alone, over a 200-day time horizon.
| Measure | Mean relative reduction (%) and 95% CrI | |||
|---|---|---|---|---|
| 7-day routine testing | Infection | Hospitalization | Death | |
| NP sampling | 1-day turnaround | 41.5 (39.3, 43.8) | 38.6 (31.9, 45.0) | 45.4 (24.4, 59.9) |
| 2-day turnaround | 29.5 (27.2, 31.7) | 25.3 (17.2, 31.9) | 24.4 (0.01, 43.3) | |
| Saliva sampling | 1-day turnaround | 33.4 (31.0, 35.5) | 28.4 (23.0, 36.8) | 28.8 (0.1, 46.4) |
| 2-day turnaround | 25.3 (22.6, 28.1) | 26.2 (16.9, 33.8) | 20.5 (−0.04, 37.7) | |
| Vaccination | 88.9 (88.4, 89.4) | 87.8 (84.3, 90.6) | 89.7 (83.5, 95.9) | |